Through a randomised placebo-controlled trial design, ISAP aims to deliver on these opportunities for oral semaglutide while also providing a valuable biomarker dataset linking gold standard PET measures of cortical tau and neuroinflammation to promising plasma and digital biomarkers relevant to preclinical AD. The gene discussed is MAPT; the disease is Alzheimer disease.